期刊文献+

三阴性乳腺癌的临床病理特点及预后因素分析 被引量:1

Clinicopathological characteristics and prognosis factors of the triple-negative breast cancer
下载PDF
导出
摘要 目的总结三阴性乳腺癌的临床病理学特点及其影响预后的因素。方法回顾性分析111例三阴性乳腺癌患者临床病理特点、复发和生存情况以及影响预后的因素。结果 111例三阴性乳腺癌占同期确诊乳腺癌患者人数的9.6%。三阴性乳腺癌患者发病年龄较轻,中位年龄为46.9岁;瘤体较大,肿瘤直径>5 cm的占21.6%(24/111);临床分期以Ⅱ、Ⅲ期为主,其中Ⅱ期59.5%(66/111),Ⅲ期29.7%(33/111)。67例(60.4%)患者伴腋窝淋巴结转移,40例(36.0%)患者出现复发或转移。单因素分析结果显示,肿瘤大小、TNM分期、淋巴结状态对患者的总生存率的影响有统计学意义。Cox多因素分析显示,肿瘤大小和腋窝淋巴结N分期是影响预后的独立危险因素。结论三阴性乳腺癌为一种独特的乳腺癌亚型,发病年龄轻,临床分期较晚,复发转移率高,预后较差。 Objective To analyze the clinicopathological characteristics and prognostic factors of the patients with tri- ple-negative breast cancer (TNBC). Methods The datas of 111 TNBC patients were retrospectively analyzed. Clinicopathological characteristics, prognostic factors and overall survival were surveyed. Results Of all the breast cancer cases registered in our hospital during this period, 111 TNBC patients accounted for approximately 9.6%. TNBC occurred mostly in young women, with a median age of 46.9 years. The tumor diameter ≥5 cm was in 24 patients (21.6%). The stage Ⅱ (59.5%) and stage Ⅲ (29.7%) were more common. Patients with the axillary lymph node metastasis accounted for 60.4% (67/111 ), 40 (36.0%) patients presented metastases or recurrence. Univariate analysis suggested that tumor size, lymph node status and TNM stage were prognostic factors of TNBC. Cox multivariate analysis demonstrated tumor size and lymph node status were independent prognostic factor. Conclusion TNBC was a special subtype of breast cancer with a recurrence and poor prognosis.
出处 《山东医药》 CAS 北大核心 2011年第48期30-32,共3页 Shandong Medical Journal
基金 广西自然科学基金项目(2011GXNSFB018102)
关键词 乳腺肿瘤 临床病理特点 预后 breast neoplasms clinicopathological characteristics prognostic
  • 相关文献

参考文献9

  • 1Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER) -negative, progesterone receptor (PR) -negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype : a population-based study from the California cancer Registry [ J ]. Cancer, 2007,109 (9) : 1721-1728.
  • 2Rakha EA, EI-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer [ J]. Cancer, 2007,109 (1) :25-32.
  • 3Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma [ J ]. Mod Pathol, 2006,19(2) :264-271.
  • 4关印,徐兵河.三阴性乳腺癌的临床病理特征及预后分析[J].中华肿瘤杂志,2008,30(3):196-199. 被引量:63
  • 5Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes [ J ]. Hum Pathol, 2006,37(9) :1217-1226.
  • 6Sasa M, Bando Y, TakMmshi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triplenegative breast cancer [ J]. J Surg Oncol, 2008,97 (1) :30-34.
  • 7Haffty BG, Yang Q, Reiss M, et al. I.ocoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer [ J ]. J Clin Oncol, 2006,24 (36) :5652-5657.
  • 8袁中玉,王树森,高岩,苏争艳,罗文标,管忠震.305例三阴乳腺癌患者的临床特征及预后因素分析[J].癌症,2008,27(6):561-565. 被引量:161
  • 9Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer [ J ]. Breast Cancer Res Treat, 2009,115 ( 2 ) :423-428.

二级参考文献34

  • 1赵卫红,徐兵河,张频,李青,赵龙妹,孙燕.乳腺癌合并脉管瘤栓的临床病理特点及预后因素分析[J].中华肿瘤杂志,2007,29(2):137-140. 被引量:14
  • 2Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 2006, 295:2492-2502.
  • 3Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recoannendations. J Natl Compr Canc Netw, 2006, 4 Suppl 3 :S1-22.
  • 4Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol, 2007, 8:235-244.
  • 5Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer, 2007, 109:25-32.
  • 6Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc, 2002, 77:148-154.
  • 7Kandel MJ, Stadler Z, Masciari S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). Proc Am Soc Clin Oncol, 2006, 24 :abstr 508.
  • 8Herr A, Gluz O, Ting E, et al. Biological characteristics in triple negative high risk breast cancer and their clinical implications. Proc Am Soc Clin Oncol, 2006, 24 : abstr 20032.
  • 9Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol, 2006, 19:264-271.
  • 10Banerjee S, Reis-Fliho JS, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol, 2006, 57:729-735.

共引文献206

同被引文献14

  • 1Perou CM,Srlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
  • 2Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci U S A,2003,100(14):8418-8423.
  • 3Scawn R,Shousha S.Morphologic spectrum of estrogen receptor-negative breast carcinoma[J].Arch Pathol Lab Med,2002,126(3):325-330.
  • 4Pracella D,Bonin S,Barbazza R,et al.Are breast cancer molecular classes predictive of survival in patients with long follow-up[J].Dis Markers,2013,35(6):595-605.
  • 5Pavlenko IA,Povilaǐtite PE,Gorelik MZ,et al.Bcl-2 as a prognostic factor in different molecular genetic subtypes of breast cancer[J].Arkh Patol,2012,74(5):36-40.
  • 6Shi YY,Nacamuli RP,Salim A,et al.The osteogenic potential of adipose-derived Mesenchymal cells is maintained with aging[J].Plast Reconstr Surg,2005,116(6):1686-1696.
  • 7Rakha EA,El2Sayed ME,Green AR,et al.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
  • 8Vuoriluoto K,Haugen H,Kiviluoto S,et al.Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer[J].Oncogene,2011,30(12):1436-1448.
  • 9Ulirsch J,Fan C,Knafl G,et al.Vimentin DNA methylation predicts survival in breast cancer[J].Breast Cancer Res Treat,2013,137(2):383-396.
  • 10Yamashita N,Tokunaga E,Kitao H,et al.Vimentin as a poor prognostic factor for triple-negative breast cancer[J].J Cancer Res Clin Oncol,2013,139(5):739-746.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部